Ighmbp2 mutations and disease pathology: Defining differences that differentiate SMARD1 and CMT2S von Ricardez Hernandez, Sara M., Ahmed, Bassil, Al Rawi, Yaser, Torres, F. Javier Llorente, Garro Kacher, Mona O., Smith, Catherine L., Al Rawi, Zayd, Garcia, Jessica, Nichols, Nicole L., Lorson, Christian L., Lorson, Monique A.

Volltext

ABT1 modifies SMARD1 pathology via interactions with IGHMBP2 and stimulation of ATPase and helicase activity von Vadla, Gangadhar P, Ricardez Hernandez, Sara M, Mao, Jiude, Garro-Kacher, Mona O, Lorson, Zachary C, Rice, Ronin P, Hansen, Sarah A, Lorson, Christian L, Singh, Kamal, Lorson, Monique A

Volltext

Defining the optimal dose and therapeutic window in SMA with respiratory distress type I model mice, FVB/NJ- Ighmpb2 nmd-2J von Shababi, Monir, Smith, Caley E, Ricardez Hernandez, Sara M, Marquez, Jose, Al Rawi, Zayd, Villalón, Eric, Farris, K David, Garro-Kacher, Mona O, Lorson, Christian L

Volltext

Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice von Aroor, Annayya R, Habibi, Javad, Kandikattu, Hemanth Kumar, Garro-Kacher, Mona, Barron, Brady, Chen, Dongqing, Hayden, Melvin R, Whaley-Connell, Adam, Bender, Shawn B, Klein, Thomas, Padilla, Jaume, Sowers, James R, Chandrasekar, Bysani, DeMarco, Vincent G

Volltext

Development of a novel severe mouse model of spinal muscular atrophy with respiratory distress type 1: FVB-nmd von Shababi, Monir, Smith, Caley E., Kacher, Mona, Alrawi, Zayd, Villalón, Eric, Davis, Daniel, Bryda, Elizabeth C., Lorson, Christian L.

Volltext

The Ighmbp2 D564N mouse model is the first SMARD1 model to demonstrate respiratory defects von Smith, Caley E, Lorson, Monique A, Ricardez Hernandez, Sara M, Al Rawi, Zayd, Mao, Jiude, Marquez, Jose, Villalón, Eric, Keilholz, Amy N, Smith, Catherine L, Garro-Kacher, Mona O, Morcos, Toni, Davis, Daniel J, Bryda, Elizabeth C, Nichols, Nicole L, Lorson, Christian L

Volltext

The Ighmbp2D564N mouse model is the first SMARD1 model to demonstrate respiratory defects von Smith, Caley E, Lorson, Monique A, Ricardez Hernandez, Sara M, Al Rawi, Zayd, Mao, Jiude, Marquez, Jose, Villalón, Eric, Keilholz, Amy N, Smith, Catherine L, Garro-Kacher, Mona O, Morcos, Toni, Davis, Daniel J, Bryda, Elizabeth C, Nichols, Nicole L, Lorson, Christian L

Volltext

Defining the optimal dose and therapeutic window in SMA with respiratory distress type I model mice, FVB/NJ-Ighmpb2 von Shababi, Monir, Smith, Caley E., Ricardez Hernandez, Sara M., Marquez, Jose, Al Rawi, Zayd, Villalón, Eric, Farris, K. David, Garro-Kacher, Mona O., Lorson, Christian L.

Volltext

Defining the optimal dose and therapeutic window in SMA with respiratory distress type I model mice, FVB/NJ-Ighmpb2nmd-2J von Shababi, Monir, Smith, Caley E., Ricardez Hernandez, Sara M., Marquez, Jose, Al Rawi, Zayd, Villalón, Eric, Farris, K. David, Garro-Kacher, Mona O., Lorson, Christian L.

Volltext

Simultaneous determination of niacin, niacinamide and nicotinuric acid in human plasma von Pfuhl, P., Kärcher, U., Häring, N., Baumeister, A., Tawab, Mona Abdel, Schubert-Zsilavecz, M.

Volltext